‘Sun Pharma to lower drug prices for Americans’

By Sohail Khan 1 September 2026, 1:08 am

Benchmarks
Nifty24,080.40-95.25

Precious Metal
Gold (MCX) (Rs/10g.)154,456.00-1825.0

Enter search text:

Business News›Industry›Healthcare/Biotech›Pharmaceuticals›Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

Read Today's Paper

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says
Synopsis

Nine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of companies to twenty-six manufacturers. The deals cover medicines for chronic and rare diseases, benefiting Medicaid programs. Sun Pharma will contribute antibiotics to the US Strategic Active Pharmaceutical Ingredients Reserve. These initiatives aim to reduce reliance on foreign suppliers and lower costs.

Listen to this article in summarized format

Loading…
×
×

Unlock AI Briefing and Premium Content

New Year Offer 24 Hours Left
Already a member? Sign In

What's Included

Exclusive Stories
Daily ePaper Access
Smart Market Tools
Curated Investment Ideas
Ad-lite Experience
Subscription

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says — Sun Pharma has been named one among nine pharmaceutical manufacturers to lower drug prices for Americans

US President Donald Trump on Monday said nine pharmaceutical manufacturers, including Sun Pharma, have reached agreements with his administration to lower prescription drug prices for Americans in line with the lowest prices paid in other developed nations

The agreements bring the total number of pharmaceutical manufacturers with most-favoured-nation (MFN) pricing deals with the administration to 26, covering 89% of the branded drug market, according to the White House.

The other eight companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Teva Pharmaceuticals and UCB.

Sun Pharma to contribute antibiotics to US reserve

As part of the agreement, Sun Pharma has committed to contribute active pharmaceutical ingredients (APIs) to the US Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), aimed at reducing the country's reliance on foreign suppliers and strengthening supplies during emergencies.

Sun Pharma will contribute 71.4 tonnes of clindamycin and 6.75 tonnes of doxycycline, both antibiotics used to treat bacterial infections, to the reserve.

The nine manufacturers have collectively committed to invest at least $19.6 billion in US manufacturing in the near term, according to the White House.

Other companies also agreed to contribute APIs to the reserve. UCB will contribute 163 tonnes of levetiracetam, while Teva Pharmaceuticals will contribute 45 tonnes of metronidazole and 4.8 tonnes of amlodipine. Astellas will contribute 25 kg of tacrolimus, an immunosuppressant used to prevent organ rejection following organ transplants.

Also read: Trump keeps teasing a third term, but is suddenly talking like a president on his way out

Trump administration targets lower drug prices

The White House said the latest agreements build on Trump's broader push to bring US prescription drug prices in line with those paid in other developed countries.

Trump signed an executive order in May 2025 directing his administration to pursue MFN prescription drug pricing. In July that year, he sent letters to 17 leading pharmaceutical manufacturers demanding steps to bring US drug prices down to the lowest prices offered in other developed nations.

Pfizer became the first drugmaker to reach an MFN agreement with the administration in September 2025. Since then, the administration has announced agreements with several major pharmaceutical companies, including Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie and Regeneron.

The administration launched TrumpRx.gov in February 2026, allowing patients to access discounts on several high-priced medicines. The White House said patients have saved more than $700 million through the programme since its launch.

The Council of Economic Advisers estimates that Trump's MFN agreements could generate $600 billion in savings over the next decade, according to the White House.

Trump has also called on Congress to pass his proposed Great Healthcare Plan, which would aim to lower drug prices and insurance premiums while increasing price transparency.

The report comes around three days after Bloomberg News reported that Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies. The report said that the firms would agree to provide discounts on outpatient drugs to state Medicaid programs such that the prices states pay align with what the companies charge in foreign countries.

Add as a Reliable and Trusted News Source
Add Now!

(You can now subscribe to our WhatsApp channel)

(Catch all the Business News, Breaking News and Latest News Updates on The .)

…moreless

(You can now subscribe to our WhatsApp channel)

Read More News on
sun pharmaSun PharmaSun Pharma newsSun Pharma share priceUS Strategic Active Pharmaceutical Ingredients ReserveDonald TrumpSun Pharma drug price reductionlower drug prices for Americanswhite housepfizer

(Catch all the Business News, Breaking News and Latest News Updates on The .)

…moreless

Enter search text:

Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories

& personalised newsletters
Login Now

Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &

in-depth stock reports
Subscribe Now

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Subscribe to gain powerful insights on business, stock market and industry trends.

Big Price Drop! Flat 40% Off

Student Only Offer

Already a Member? Sign In now

Already a Member? Sign In now
Already a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail Offer
Avail Offer

Claim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004

' + h3 + '

' + h4 + '

' + listing + '

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with in-depth insights that matter

Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

The problem with lab grown diamonds
Why a falling rupee is a better option for the economy

A list of top 20 momentum stocks that have delivered massive returns in one year